Vivos Inc. 近日宣布,公司在为其核心产品Radiogel®精准放射性核素疗法™向美国食品药品监督管理局(FDA)提交研究器械豁免(IDE)申请的工作中,取得了显著进展。这一关键里程碑标志着该疗法向临床应用迈出了重要一步。
Vivos Inc. 近日宣布,公司在为其核心产品Radiogel®精准放射性核素疗法™向美国食品药品监督管理局(FDA)提交研究器械豁免(IDE)申请的工作中,取得了显著进展。这一关键里程碑标志着该疗法向临床应用迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.